酒石酸泰瑞西利胶囊

Search documents
多只港股股价创历史新高
证券时报· 2025-08-20 05:17
Core Viewpoint - The Hong Kong stock market is currently experiencing a period of intensive mid-term earnings disclosures, leading to significant stock price fluctuations for various companies [1][2]. Group 1: Earnings Performance - As of August 20, over 800 companies have reported their mid-term earnings for 2025, with some companies seeing their stock prices soar due to better-than-expected performance, while others faced significant declines due to differing market growth expectations, indicating a "structural differentiation" in the market [2]. - Fuyao Glass and Pop Mart achieved record highs in their stock prices following strong earnings reports, with Fuyao Glass reaching HKD 69.05 per share and Pop Mart surpassing HKD 305 per share [5][9]. - Fuyao Glass reported a revenue of CNY 21.447 billion for the first half of 2025, a year-on-year increase of 16.94%, and a net profit of CNY 4.8 billion, up 37.33% [7]. - Pop Mart's revenue for the first half of 2025 was CNY 13.88 billion, a remarkable year-on-year growth of 204.4%, with an adjusted net profit of CNY 4.71 billion, up 362.8% [9]. - Chow Sang Sang's stock price surged over 27% to HKD 11.42 per share after announcing an expected net profit of HKD 900 million to HKD 920 million for the first half of 2025, compared to HKD 502 million in the same period last year [11]. Group 2: Underperforming Companies - Yancoal Australia saw its stock price drop over 9% on August 20 due to disappointing earnings results, with a reported revenue of AUD 2.675 billion, a year-on-year decrease of 15%, and a net profit of AUD 163 million, down 61% [14][16]. - The decline in Yancoal Australia's performance was attributed to a general drop in global coal prices, with the average selling price of self-produced coal falling 15% to AUD 149 per ton [16]. - Several pharmaceutical stocks also experienced declines, with companies like Simcere Pharmaceutical and Hansoh Pharmaceutical seeing drops exceeding 7% following underwhelming earnings reports [17].
多只港股股价创历史新高
Zheng Quan Shi Bao· 2025-08-20 05:09
福耀玻璃、泡泡玛特等刷新上市以来纪录 Wind数据显示,截至目前,已有超800家公司公布了2025年中期业绩,其中部分公司因业绩超预期股价 飙升,甚至刷新上市以来新高,而部分行业龙头则因市场对未来增长预期的分歧出现大幅回调,市场呈 现"结构性分化"特征。 目前,港股市场进入中期业绩密集披露期,多只港股在业绩公布后,股价波动明显。 在业绩驱动下,多只个股凭借强劲的财务数据和战略布局实现股价大涨,甚至刷新上市以来纪录。 8月20日,在港股整体表现疲软背景下,业绩表现良好的福耀玻璃、泡泡玛特等盘中大涨,股价刷新历 史纪录。 8月20日,福耀玻璃港股的股价一度攀升至69.05港元/股,刷新上市以来新高。 8月19日晚,福耀玻璃披露2025年半年报。公司上半年实现营业收入214.47亿元,同比增长16.94%;实 现归属于上市公司股东的净利润48亿元,同比增长37.33%。公司拟进行中期利润分配,拟每股分配现 金股利0.90元(含税),合计派发现金股利23.5亿元。 泡泡玛特在中期业绩公布后,公司股价一度突破300港元关口,攀升至305港元/股,刷新上市以来新 高,总市值超过4000亿港元。 兖煤澳大利亚的半年报显示, ...
“创新药第一股”半年报净利润首次下滑,同比降超三成
Xin Lang Cai Jing· 2025-08-20 01:49
8月19日晚间,贝达药业(300558.SZ)披露半年报,上半年实现营业收入17.31亿元,同比增长 15.37%;归属净利润1.4亿元,同比下降37.53%。 这是公司自2022年之后,首次在半年报出现净利润同比下滑现象。贝达药业表示,因计入当期损益的折 旧摊销等费用升高,归属净利润出现了一定程度的下降。 元。 公司在2025年半年度报告中提到,报告期内的经营业务主要围绕创新药物的研发和销售。公司已有八款 药品上市新产品,包括盐酸埃克替尼片、盐酸恩沙替尼胶囊等核心产品。 另外,甲磺酸贝福替尼胶囊和伏罗尼布片在纳入医保后销售加快,酒石酸泰瑞西利胶囊于2025年6月获 批上市。此外,公司宣布暂停开发BPB-101项目,并透露MCLA-129在肺癌领域的II期研究已完成首例 患者入组。 多款新药集中上市利好的同时,公司资金却有所承压。截至上半年末,贝达药业流动资产为13.59亿 元,低于17.57亿元的流动负债。 其中,2025年一季报营业收入为9.18亿元,同比上升24.7%;归母净利润为1.0亿元,同比上升2.0%;扣 非归母净利润为1.64亿元,同比上升83.6%。 据智通财经报道,贝达药业目前有拖欠合作方 ...
“上市快+出海热” 国产创新药向新提质迎新机
Shang Hai Zheng Quan Bao· 2025-07-30 18:03
Group 1 - The Chinese innovative drug industry is transitioning from "follow-up innovation" to "global leadership," with a record number of innovative drugs approved in the first half of the year [1][2] - In the first half of 2023, 43 innovative drugs were approved in China, representing a 59% year-on-year increase, compared to only 48 approvals for the entire year of 2024 [2][3] - China's innovative drug R&D pipeline accounts for about one-fourth of the global total, with approximately 3,000 clinical trials conducted annually, placing China at the forefront of global innovative drug development [2][3] Group 2 - Companies like Fosun Pharma and Hengrui Medicine have successfully launched multiple innovative drugs, with Hengrui having 23 first-class innovative drugs and 4 second-class innovative drugs approved domestically [3][4] - The commercialization of innovative drugs is leading to a recovery in performance for domestic pharmaceutical companies, with companies like Luoxin Pharma and MicuRx reporting significant profit increases [3][4] - The trend of Chinese pharmaceutical companies expanding internationally is accelerating, with a shift from license-in to explosive growth in license-out transactions, contributing nearly 50% of the total transaction value globally [4][5] Group 3 - Notable license-out deals include a partnership between 3SBio and Pfizer, with an upfront payment of $1.25 billion and a potential total deal value of $6.05 billion, setting a record for Chinese innovative drugs [5][6] - The rapid growth of license-out transactions is providing substantial cash flow for domestic innovative drug companies, supporting their core pipelines overseas and creating more collaboration opportunities with multinational pharmaceutical companies [6]
7月3日早间重要公告一览
Xi Niu Cai Jing· 2025-07-03 04:16
Group 1: Nanjing Business Travel - Nanjing Business Travel (600250) expects a net profit of 6 million to 9 million yuan for the first half of 2025, a decrease of 67.4% to 78.27% year-on-year [1] - The net profit excluding non-recurring gains and losses is expected to be between 5.5 million and 8.5 million yuan, down 17.34% to 46.52% year-on-year [1] Group 2: Jihong Co., Ltd. - Jihong Co., Ltd. (002803) anticipates a net profit of 112 million to 119 million yuan for the first half of 2025, an increase of 55% to 65% year-on-year [2] - The net profit excluding non-recurring gains and losses is expected to be between 106 million and 113 million yuan, up 68.16% to 79.62% year-on-year [2] - Basic earnings per share are projected to be between 0.29 yuan and 0.31 yuan [2] Group 3: Zhuhai Design - Zhuhai Design (300564) announced that its actual controller plans to reduce holdings by up to 3% of the company's shares, totaling 483.95 million shares [3] Group 4: Anjisi - Anjisi (688581) disclosed that two shareholders plan to reduce their holdings by up to 2% of the company's shares, totaling 162.27 million shares [4] Group 5: Jingwei Huikai - Jingwei Huikai (300120) intends to acquire a total of 12.44% equity in Nuo Si Wei, with a total transaction price of approximately 1.49 billion yuan [4] - The acquisition will increase the company's control over Nuo Si Wei from 22.12% to 34.56% [4] Group 6: Hainan Highway - Hainan Highway (000886) is planning to purchase 51% equity in Hainan Jiao Control Petrochemical, which will become a subsidiary after the transaction [9] Group 7: *ST Modern - *ST Modern (002656) has applied to revoke other risk warnings but will still face delisting risk warnings due to financial indicators [10] Group 8: Ningde Times - Ningde Times (300750) has repurchased 6.641 million A-shares at a total cost of 1.551 billion yuan [11][12] Group 9: Lixun Precision - Lixun Precision (002475) is planning to issue H shares and list on the Hong Kong Stock Exchange [13] Group 10: Ruikang Pharmaceutical - Ruikang Pharmaceutical (002589) announced that its vice president has been placed under detention by the local supervisory committee [14] Group 11: Changchun High-tech - Changchun High-tech (000661) announced that its subsidiary has received approval for a new drug, a monoclonal antibody for gout treatment [15] Group 12: Guofang Group - Guofang Group (002708) plans to reduce its holdings by up to 1.45% of the company's shares, totaling 666 million shares [16] Group 13: Guangyang Co., Ltd. - Guangyang Co., Ltd. (002708) announced that shareholders plan to reduce their holdings by up to 1.65% of the company's shares, totaling 922.76 million shares [17] Group 14: Zhixin Precision - Zhixin Precision (301512) disclosed that a major shareholder plans to reduce holdings by up to 1.86% of the company's shares, totaling 99 million shares [18] Group 15: Xinzhou Bang - Xinzhou Bang (300037) announced that its directors and executives plan to reduce their holdings by up to 126.88 million shares [19] Group 16: Guoanda - Guoanda (300902) announced that its actual controllers plan to reduce their holdings by up to 362 million shares [20]
医保目录调整在即;苑东生物董事被查|21健讯Daily
2 1 Shi Ji Jing Ji Bao Dao· 2025-07-03 02:34
Policy Developments - The National Healthcare Security Administration (NHSA) is soliciting public opinions on the draft adjustment plan for the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance drug catalog, as well as the commercial health insurance innovative drug catalog [2] - The first version of the commercial health insurance innovative drug catalog will be established in 2025, focusing on innovative drugs with high clinical value that cannot be included in the basic catalog [2] Drug and Device Approvals - JinSai Pharmaceutical's monoclonal antibody drug, Firsekibart, has been approved for the treatment of acute gouty arthritis in adults who are intolerant to or have contraindications for non-steroidal anti-inflammatory drugs and/or colchicine [4] - Betta Pharmaceuticals' innovative drug, Tazemetostat, has been approved for the treatment of locally advanced or metastatic breast cancer in adults who have progressed after endocrine therapy [5] - Xiansheng Pharmaceutical's monoclonal antibody, Suweisitabant, has been approved for the treatment of recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in adults who have received no more than one prior systemic therapy [6] Capital Markets - Merida Biosciences, a U.S. biotech company, has raised $121 million in Series A financing, setting a record for Series A funding in the autoimmune field [8] Industry Events - Former Takeda China President, Dan Guohong, will join BeiGene as General Manager for Greater China, Central Asia, and South Asia, starting August 18, 2025 [10] - Yuan Dong Bio's independent director, Peng Long, is under disciplinary review and investigation for serious violations of discipline and law [12] - KangLe WeiShi announced that its shareholder, Tianlangxing Holdings Group, has reduced its holdings by 1.6953 million shares, accounting for 0.6034% of the company's total share capital [13]
【早报】证监会:始终把维护市场稳定作为监管工作首要任务;8月1日起,现金买黄金超10万元将需上报
财联社· 2025-07-02 22:59
Regulatory News - The China Securities Regulatory Commission emphasizes maintaining market stability as a primary regulatory task and promotes the establishment of a normalized market stabilization mechanism [1][5] - Starting from August 1, cash purchases of gold exceeding 100,000 yuan will need to be reported [2][3] Industry News - In June, 1.65 million new A-share accounts were opened, representing a year-on-year increase of 53% [2][6] - The Guangzhou Housing Provident Fund Management Center is soliciting opinions on a draft policy for converting commercial loans to public housing loans when the personal loan rate is below 75% [7] - The Shanghai superconducting material and headquarters base, with an investment of 2.5 billion yuan, has officially started construction, marking it as the largest project in the superconducting field globally [8] - The average wholesale price of eggs in Beijing decreased by 11.23% month-on-month and 26.43% year-on-year in June [7] Company News - Luxshare Precision announced plans for overseas share issuance (H-shares) and listing on the Hong Kong Stock Exchange [10] - Yonghui Supermarket reported that JD World Trade has reduced its stake in the company by 1.26% during the reduction period [10] - Jiangnan Water announced that Lianan Life Insurance has increased its stake in the company through the secondary market [10] - Guizhou Moutai has repurchased 3.3821 million shares as of the end of June, with a total expenditure of 5.202 billion yuan [11] - Tianqi Lithium announced a lawsuit against Yongtai Technology for commercial secret infringement, with expected economic losses of 888 million yuan [13]